<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954966</url>
  </required_header>
  <id_info>
    <org_study_id>811940</org_study_id>
    <secondary_id>K24DA030301</secondary_id>
    <nct_id>NCT01954966</nct_id>
  </id_info>
  <brief_title>Progesterone and Brain Imaging Study</brief_title>
  <official_title>Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether a sex hormone called progesterone is helpful in
      reducing cigarette smoking and craving for cigarettes. This study also includes brain imaging
      to measure possible effects of progesterone on certain neurochemicals. These neurochemicals
      are called gamma-aminobutyric acid (or GABA for short) and glutamate. Both nicotine and
      progesterone affect these brain chemicals.

      Individuals wishing to participate in this study must be medically healthy men or women who
      smoke at least 10 cigarettes per day or greater. Participants must not suffer from a mental
      illness or use drugs other than nicotine and marijuana. Participants cannot have any
      implanted metallic devices such as pacemakers, orthodontic braces, or shrapnel. Participants
      must not have peanut allergies and must never have had a reaction to progesterone. Finally,
      participants cannot be taking any medications for anxiety, depression or insomnia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Occipital Cortex GABA Pre and Post Placebo Administration</measure>
    <time_frame>Test Day #2 and Test Day #5 - 6 total scans over the period of 2-3 months.</time_frame>
    <description>Occipital cortex GABA and glutamate concentrations pre and post placebo administration. GABA and glutamate concentrations will be obtained using the non-invasive neuroimaging method of proton magnetic resonance spectroscopy (1H-MRS) both before and after placebo administration and smoking abstinence. In total subjects will undergo 6 1H-MRS scans.
The 6 1H-MRS scans take place over a period of approximately 1-2 months. Each paradigm (placebo/progesterone) takes approximately one week, with an approximately two-week wash in between paradigms for men and an approximately 1-month wash in between paradigms for women. The subject will undergo a smoking session on Test Day #1 and Test Day #5, MRS scans are conducted on Test Day #2 (2 scans) and Test Day #5 (1 scan).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms during nicotine abstinence</measure>
    <time_frame>Baseline, on the day of scans, at each abstinence screening visit (4 times over a 2 day period between Test Day #2 and Test Day #5).</time_frame>
    <description>Withdrawal symptoms will be measured using the Nicotine Withdrawal Symptoms Checklist (NWSC). Craving will be assessed using the Brief Questionnaire on Smoking Urges (BQSU) and the Tiffany Questionnaire for Smoking Urges and mood will be assessed using a variety of ratings including the Profile of Mood States (POMS), the Visual Analogue Scale (VAS) and the Positive and Negative Affect Scales (PANAS). Effects of nicotine will be assessed using the Nicotine Effects Questionnaire (NEQ). Premenstrual syndrome symptoms will be assessed daily during the screening and study phases using the Daily Record of Severity of Problems (DRSP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Occipital Cortex GABA Pre and Post Progesterone Administration</measure>
    <time_frame>Test Day #2 and Test Day #5 - 6 total scans over the period of 2-3 months.</time_frame>
    <description>Occipital cortex GABA and glutamate concentrations pre and post progesterone administration. GABA and glutamate concentrations will be obtained using the non-invasive neuroimaging method of proton magnetic resonance spectroscopy (1H-MRS) both before and after progesterone administration and smoking abstinence. In total, subjects will undergo 6 1H-MRS scans.
The 6 1H-MRS scans take place over a period of approximately 1-2 months. Each paradigm (placebo/progesterone) takes approximately one week, with an approximately two-week wash in between paradigms for men and an approximately 1 month wash in between paradigms for women. The subject will undergo a smoking session on Test Day #1 and Test Day #5, MRS scans are conducted on Test Day #2 (2 scans) and Test Day #5 (1 scan).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Nicotine Withdrawal</condition>
  <arm_group>
    <arm_group_label>Progesterone 200 mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone 200 mg look-alike capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.</description>
    <arm_group_label>Progesterone 200 mg capsules</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.</description>
    <arm_group_label>Progesterone 200 mg look-alike capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male smokers, aged 18 to 50 years;

          -  History of smoking greater than or equal to 10 cigarettes daily for the past year, as
             per self-report (periods of smoking abstinence within the last year will be
             exclusionary at PI discretion);

          -  Not seeking treatment at the time of the study for nicotine dependence;

          -  Have a Fagerstrom Test for Nicotine Dependence (FTND) score of at least 3 and a Carbon
             Monoxide (CO) level greater than or equal to 11 ppm;

          -  Clean urine drug screen (marijuana is permissible);

          -  In good health as verified by medical history;

          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding.

        Exclusion Criteria:

          -  History of major medical illness: including liver diseases, abnormal vaginal bleeding,
             suspected or known malignancy; thrombophlebitis; deep vein thrombosis; pulmonary
             embolus; clotting or bleeding disorders; heart disease; diabetes; history of stroke or
             other medical conditions that the physician investigator deems as contraindicated for
             the patient to be in the study;

          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics) and recent (within previous year) psychiatric diagnosis and treatment for
             Axis I disorders including major depression, bipolar affective disorder, generalized
             anxiety disorder, post-traumatic stress disorder and panic disorder;

          -  Lifetime history of schizophrenia or other psychotic disorder;

          -  Lifetime substance dependence disorder, excepting nicotine, alcohol and marijuana, as
             per SCID interview

          -  Substance use disorders within the previous 2 years, excepting nicotine, as per SCID
             interview

          -  Regular use of any other tobacco products than cigarettes, including smokeless tobacco
             and nicotine products;

          -  Known allergy to progesterone or peanuts (vehicle for micronized progesterone).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia N Epperson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Psychiatry, University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lipner, B.A.</last_name>
    <phone>(215) 573-8873</phone>
    <email>lipnere@upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Iannelli, MS</last_name>
    <phone>215-417-8839</phone>
    <email>sclaud@mail.med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn Center for Women's Behavioral Wellness</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Iannelli, M.S.</last_name>
      <phone>215-417-8839</phone>
      <email>sclaud@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia N Epperson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/womenswellness/</url>
    <description>Center Website</description>
  </link>
  <reference>
    <citation>Epperson CN, O'Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, Mason GF. Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry. 2005 Jan 1;57(1):44-8.</citation>
    <PMID>15607299</PMID>
  </reference>
  <reference>
    <citation>Cai K, Nanga RP, Lamprou L, Schinstine C, Elliott M, Hariharan H, Reddy R, Epperson CN. The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T Â¹H-MRS study. Neuropsychopharmacology. 2012 Dec;37(13):2764-71. doi: 10.1038/npp.2012.142. Epub 2012 Aug 8.</citation>
    <PMID>22871916</PMID>
  </reference>
  <reference>
    <citation>Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O'Malley SS. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend. 2010 Nov 1;112(1-2):1-8. doi: 10.1016/j.drugalcdep.2010.04.021. Epub 2010 Jun 19.</citation>
    <PMID>20561758</PMID>
  </reference>
  <reference>
    <citation>Mason GF, Petrakis IL, de Graaf RA, Gueorguieva R, Guidone E, Coric V, Epperson CN, Rothman DL, Krystal JH. Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. Biol Psychiatry. 2006 Jan 1;59(1):85-93. Epub 2005 Nov 14.</citation>
    <PMID>16289397</PMID>
  </reference>
  <reference>
    <citation>Cosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, Perry E, Maciejewski PK, Epperson CN, Allen S, O'malley S, Mazure CM, Seibyl JP, van Dyck CH, Staley JK. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med. 2007 Oct;48(10):1633-40. Epub 2007 Sep 14.</citation>
    <PMID>17873128</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

